ALB and Cirrhosis: In fact, empiric administration of volume expanders without a sense of intravascular volume status may explain recent detrimental effects of albumin administration in hospitalized patients with cirrhosis (China et al., 2021) or the unexpected harm noted in terlipressin administered too late in type 1 hepatorenal syndrome (Wong et al., 2021).